Navigation Links
Lumension Security Announces General Availability of Sanctuary Endpoint Protection and Data Protection Suite to Safeguard Data and Privacy
Date:8/4/2008

encryption solutions. PGP® enterprise data protection solutions help organizations comply with FIPS-140-2 standards and provide centralized encryption key management and support for large secondary hard drives. Using PGP® encryption with the Sanctuary technology, administrators can easily establish and enforce granular encryption policies for removable storage devices, review device usage logs, and monitor the content of data transferred to and from devices.

"Protecting data is more important than ever given the mounting security risks associated with today's mobile workforce and compliance mandates. At all times, we need to know that no confidential data leaves the premises that should not and no malware infects our network via virus-laden device or rogue application," said Rob Israel, CIO, John C. Lincoln Health Network. "Lumension Security's http://www.lumension.com/industry.jsp?id=121084&rpLangCode=1&rpMenuId=118395&rpLeadSourceId=2006 [Endpoint Protection and Data Protection Suite __title__ Sanctuary Endpoint and Data Protection] allows us to be proactive, yet flexible with the data encryption and enforcement of policies around employee device and application use. What's more, this powerful solution extends our control over CD and DVD data by allowing us to reduce risk of data loss and theft by encrypting and protecting easily accessible information while enabling end user productivity."

Sanctuary Delivers Key Benefits:


Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5

Related medicine news :

1. Presidential Candidates Address Health, Financial Security at AARPs Life@50+
2. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
3. Digital Info Security Company and DGF MedServ, Inc. Announce Intent to Partner in Marketing DGIF IT Solutions to Medical Industry
4. Report highlights inadequate pandemic planning as a threat to EU security
5. PinnacleHealth System Selects Phoenix Health Systems to Provide HIPAA Security Assessment Services
6. Vendormate VISION 4.0(TM) Streamlines Healthcare Security and Compliance Efforts
7. HITSP Defines Overarching Set of Healthcare Security and Privacy Standards
8. New Records & Information Management: Are You Spending Right on Records Management, Data Security and Compliance?
9. Divided We Fail Faith Week to Raise Health and Financial Security Issues in Communities of Faith
10. TraceSecurity Announces Partnership with PHNS Expanding Compliance Services to Hundreds of Healthcare Systems
11. New T-ray Source Could Improve Airport Security, Cancer Detection
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lumension Security Announces General Availability of Sanctuary Endpoint Protection and Data Protection Suite to Safeguard Data and Privacy
Lumension Security Announces General Availability of Sanctuary Endpoint Protection and Data Protection Suite to Safeguard Data and Privacy
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3NASA Research Reveals Major Insight Into Evolution of Life on Earth 4870 1NASA Research Reveals Major Insight Into Evolution of Life on Earth 4870 2The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 1The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 2The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 3The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 4Patch Shots May Someday Replace Injections 54893 1Patch Shots May Someday Replace Injections 54893 2
Other Medicine Technology:New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 2SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 3SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 4SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 5SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 7